Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $49.97M (cash outflow) rose 65.0% year over year, ahead of the +50.1% change in trailing-twelve-month net income. Sequentially, it rose 21.3% from the prior quarter. Over 3 fiscal years it compounded at +119.8% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$98.71M (-6.4%) for the fiscal year ending Dec 2026, a slowdown from the +25.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$49.97M+21.3% QoQ
- Last fiscal yearDec 2025
- -$105.43M+25.9% YoY
- LTMSep 2026
- -$152.57M+50.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +65.0% | +2.4% | -62.6 pp |
| 1 year | +25.9% | -6.4% | -32.3 pp |
| 3-year CAGR | +119.8% | +20.0% | -99.8 pp |
| 5-year CAGR | +15.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (105.43M) USD
- Year-over-year change
- -25.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (105.43M) | -25.9% |
| FY2024 | 2024-12-31 | (83.72M) | — |
| FY2022 | 2022-12-31 | (9.93M) | +48.6% |
| FY2021 | 2021-12-31 | (19.32M) | -98.4% |
| FY2020 | 2020-12-31 | (9.74M) | — |
Net Income vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 net income of $152.57M is the 4th largest of the 10 companies compared; the peer median is $71.19M.
- Its year-over-year change of +50.1% is the 5th highest of 10, against a peer median of +35.2%.
- Over three fiscal years its annual growth of +119.8% compares with a peer median of +29.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
| LTM Jun 2026 | $192.25M | +67.5% | +78.6% | 10097.0% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $152.57M | +50.1% | +119.8% | — |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Jun 2026 | $71.19M | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| FY2025 | $60.9M | +35.2% | — | 4511.0% | |
| FY2025 | $55.48M | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $26.79M | -81.0% | — | 11.5% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $71.19M | +35.2% | +29.5% | 4511.0% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (19.32M) | (9.93M) | (83.72M) | (105.43M) |
| Depreciation & Amortization | 93K | 91K | 114K | 27K | 83K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.88M | (28K) | (1.66M) | 11.59M | (2.56M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.1M | (411K) | (783K) | 3.46M | 693K |
| Other Working Capital | 776K | 383K | (878K) | 8.13M | (3.25M) |
| Other Non-Cash Items | 43K | 497K | 561K | 14.27M | 19.7M |
| Operating Cash Flow | (7.73M) | (18.76M) | (10.91M) | (57.84M) | (88.21M) |
| Capital Expenditures | (19K) | (43K) | (2K) | (189K) | (209K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (329.94M) | (520.96M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 424.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19K) | (43K) | (2K) | (330.13M) | (96.75M) |
| Debt Repayment | (408K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 48.86M | 23.09M | 0 | 449.54M | 170.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 48.45M | 23.09M | 0 | 449.54M | 170.32M |
| Effect of Forex Changes | 0 | 0 | 0 | (37.43M) | 0 |
| Net Change in Cash | 40.71M | 4.29M | (10.91M) | 24.14M | (14.64M) |
| Free Cash Flow | (7.74M) | (18.81M) | (10.91M) | (58.03M) | (88.42M) |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.